or Try an Advanced Search...

    Technical Analysis for CMPX - Compass Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.54 -4.64% -0.08
    CMPX closed down 4.64 percent on Wednesday, May 15, 2024, on 2.03 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CMPX trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.64%
    20 DMA Support Bullish -4.64%
    Pocket Pivot Bullish Swing Setup -4.64%
    Inside Day Range Contraction -4.64%
    Gapped Down Weakness -4.64%
    20 DMA Support Bullish -1.28%
    Wide Range Bar Range Expansion -1.28%
    Outside Day Range Expansion -1.28%
    Older End-of-Day Signals for CMPX ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 12 hours ago
    Down 1% about 12 hours ago
    60 Minute Opening Range Breakdown about 14 hours ago
    2x Volume Pace about 14 hours ago
    1.5x Volume Pace about 14 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CMPX Chart by TradingView
    Basic chart:

    Profile

    Compass Therapeutics, Inc. Description

    Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Its scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company's pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Clinical Medicine Immune System Antibodies Oncology Tumor Human Diseases Immune Checkpoint Angiogenesis Tumor Microenvironment Oncology Focused Biopharmaceutical

    Is CMPX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    May 13 Compass Therapeutics GAAP EPS of -$0.08
    May 13 Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
    Apr 25 Compass gains FDA Fast Track status for biliary tract cancer candidate
    Apr 25 Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
    Apr 16 Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
    Apr 12 Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
    Apr 10 Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
    Apr 9 Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    Mar 21 Compass Therapeutics reports FY results
    See more CMPX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.61
    52 Week Low 1.15
    Average Volume 336,784
    200-Day Moving Average 1.83
    50-Day Moving Average 1.76
    20-Day Moving Average 1.55
    10-Day Moving Average 1.62
    Average True Range 0.15
    RSI (14) 43.50
    ADX 14.76
    +DI 15.62
    -DI 16.84
    Chandelier Exit (Long, 3 ATRs) 1.35
    Chandelier Exit (Short, 3 ATRs) 1.77
    Upper Bollinger Bands 1.72
    Lower Bollinger Band 1.39
    Percent B (%b) 0.46
    BandWidth 21.23
    MACD Line -0.03
    MACD Signal Line -0.04
    MACD Histogram 0.0117
    Fundamentals Value
    Market Cap 196.33 Million
    Num Shares 127 Million
    EPS -0.33
    Price-to-Earnings (P/E) Ratio -4.67
    Price-to-Sales 0.00
    Price-to-Book 1.16
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.77
    Resistance 3 (R3) 1.79 1.74 1.73
    Resistance 2 (R2) 1.74 1.68 1.73 1.71
    Resistance 1 (R1) 1.64 1.65 1.62 1.62 1.70
    Pivot Point 1.59 1.59 1.58 1.58 1.59
    Support 1 (S1) 1.49 1.53 1.47 1.47 1.38
    Support 2 (S2) 1.44 1.50 1.43 1.37
    Support 3 (S3) 1.34 1.44 1.35
    Support 4 (S4) 1.32